Longeveron Inc.
Longeveron Inc. (Nasdaq: LGVN) is a clinical-stage biotechnology company developing regenerative medicines, with its lead investigational product, laromestrocel, also known as Lomecel-B®, a donor-derived bone marrow mesenchymal stem cell therapy. The company is developing laromestrocel for hypoplastic left heart… From the company’s description.
Over the twelve months to Jun 30, 2026, Longeveron Inc. reported revenue of $1.19M, down 42.7% from a year earlier, and a net loss of $23.47M. Operations used $20.37M in cash. In fiscal 2025, it reported revenue of $1.20M, down 49.9% from fiscal 2024, and a net loss of $22.70M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Longeveron Inc. does
In the company’s own words
Longeveron Inc. (Nasdaq: LGVN) is a clinical-stage biotechnology company developing regenerative medicines, with its lead investigational product, laromestrocel, also known as Lomecel-B®, a donor-derived bone marrow mesenchymal stem cell therapy. The company is developing laromestrocel for hypoplastic left heart syndrome, mild Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty; its lead program is an ongoing Phase 2b trial for hypoplastic left heart syndrome. Longeveron manufactures investigational products for early-stage clinical trials and occasionally provides contract manufacturing and development services to other companies. It operates a cGMP manufacturing facility in Miami with eight cleanrooms and two research and development laboratories, while planning to use a contract manufacturer for potential commercial-scale production. The company has no subsidiaries and describes its business around a single product candidate rather than reportable operating segments. Founded in 2014, Longeveron has completed five U.S. clinical studies of laromestrocel and operates a registry trial in The Bahamas. It has no established sales or product-distribution infrastructure.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- December
- CIK
- 1721484
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Longeveron Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Longeveron Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Longeveron Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Longeveron Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Longeveron Inc.'s last four quarterly filings that the numbers alone won't show?”